Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol in Binge Eating Disorder
NCT04602936Phase 4Unknown
- Sponsor
- Lindner Center of HOPE
- Start
- Jun 2021
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in binge eating disorder (BED) comparing Solriamfetol with Placebo (2 arms). Primary endpoint: Binge-eating day frequency. Status: unknown.
02
Drugs
solriamfetol
03
Conditions
binge eating disorder (BED)
Beyond the preview
Go deeper on NCT04602936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602936.